
Xttrium 0.12% CHG Oral Rinse

Chlorhexidine Gluconate 0.12%, Oral Rinse, USP Rx Only, NDC 0116-2001-16, 0116-2001-04, 0116-2001-15, 0116-2001-05

CLINICAL PHARMACOLOGY

Chlorhexidine gluconate oral rinse provides antimicrobial activity during oral rinsing. The clinical significance of chlorhexidine gluconate oral rinse's antimicrobial activities is not clear. Microbiological sampling of plaque has shown a general reduction of counts of certain assayed bacteria, both aerobic and anaerobic, ranging from 54–97% through six-months use.

Use of chlorhexidine gluconate oral rinse in a six-month clinical study did not result in any significant changes in bacterial resistance, overgrowth of potentially opportunistic organisms or other adverse changes in the oral microbial ecosystem. Three months after chlorhexidine gluconate oral rinse use was discontinued, the number of bacteria in plaque had returned to baseline levels and resistance of plaque bacteria to chlorhexidine gluconate was equal to that at baseline.

Pharmacokinetics: Pharmacokinetic studies with chlorhexidine gluconate oral rinse indicate approximately 30% of the active ingredient, chlorhexidine gluconate, is retained in the oral cavity following rinsing. This retained drug is slowly released into the oral fluids. Studies conducted on human subjects and animals demonstrate chlorhexidine gluconate is poorly absorbed from the gastrointestinal tract. The mean plasma level of chlorhexidine gluconate reached a peak of 0 .206 mcg/g in humans 30 minutes after they ingested a 300-mg dose of the drug. Detectable levels of chlorhexidine gluconate were not present in the plasma of these subjects 12 hours after the compound was administered. Excretion of chlorhexidine gluconate occurred primarily through the feces (~90%). Less than 1% of the chlorhexidine gluconate ingested by these subjects was excreted in the urine.

INDICATION

Chlorhexidine gluconate oral rinse is indicated for use between dental visits as part of a professional program for the treatment of gingivitis as characterized by redness and swelling of the gingivae, including gingival bleeding upon probing. Chlorhexidine gluconate oral rinse has not been tested among patients with acute necrotizing ulcerative gingivitis (ANUG). For patients having coexisting gingivitis and periodontitis, see PRECAUTIONS.

CONTRAINDICATIONS

Chlorhexidine gluconate oral rinse should not be used by persons who are known to be

hypersensitive to chlorhexidine gluconate or other formula ingredients.

WARNINGS

The effect of chlorhexidine gluconate oral rinse on periodontitis has not been determined. An increase in supragingival calculus was noted in clinical testing in chlorhexidine gluconate oral rinse users compared with control users. It is not known if chlorhexidine gluconate oral rinse use results in an increase in subgingival calculus. Calculus deposits should be removed by a dental prophylaxis at intervals not greater than six months. Anaphylaxis, as well serious allergic reactions, have been reported during postmarketing use with dental products containing chlorhexidine. SEE CONTRAINDICATIONS.

PRECAUTIONS

General Precautions

1. For patients having coexisting gingivitis and periodontitis, the presence or absence of gingival inflammation following treatment with chlorhexidine gluconate oral rinse should not be used as a major indicator of underlying periodontitis.

2. Chlorhexidine gluconate oral rinse can cause staining of oral surfaces, such as tooth surfaces, restorations, and the dorsum of the tongue. Not all patients will experience a visually significant increase in toothstaining. In clinical testing, 56% of chlorhexidine gluconate oral rinse users exhibited a measurable increase in facial anterior stain, compared to 35% of control users after six months; 15% of chlorhexidine gluconate oral rinse users developed what was judged to be heavy stain, compared to 1% of control users after six months. Stain will be more pronounced in patients who have heavier accumulations of unremoved plaque.

Stain resulting from use of chlorhexidine gluconate oral rinse does not adversely affect health of the gingivae or other oral tissues. Stain can be removed from most tooth surfaces by conventional professional prophylactic techniques. Additional time may be required to complete the prophylaxis.

Discretion should be used when prescribing to patients with anterior facial restorations with rough surfaces or margins. If natural stain cannot be removed from these surfaces by a dental prophylaxis, patients should be excluded from chlorhexidine gluconate oral rinse treatment if permanent discoloration is unacceptable. Stain in these areas may be difficult to remove by dental prophylaxis and on rare occasions may necessitate replacement of these restorations.

3. Some patients may experience an alteration in taste perception while undergoing treatment with chlorhexidine gluconate oral rinse. Rare instances of permanent taste alteration following chlorhexidine gluconate oral rinse use have been reported via post-marketing product surveillance.

Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when chlorhexidine gluconate oral rinse is administered to nursing women.

In parturition and lactation studies with rats, no evidence of impaired parturition or of toxic effects to suckling pups was observed when chlorhexidine gluconate was administered to dams at doses that were over 100 times greater than that which would result from a person's ingesting 30 ml (2 capfuls) of chlorhexidine gluconate oral rinse per day.

Pediatric Use

Clinical effectiveness and safety of chlorhexidine gluconate oral rinse have not been established in children under the age of 18.

Carcinogenesis, Mutagenesis, and Impairment of Fertility

In a drinking water study in rats, carcinogenic effects were not observed at doses up to 38 mg/kg/day. Mutagenic effects were not observed in two mammalian in vivo mutagenesis studies with chlorhexidine gluconate. The highest doses of chlorhexidine used in a mouse dominant-lethal assay and a hamster cytogenetics test were 1000 mg/kg/day and 250 mg/kg/day, respectively. No evidence of impaired fertility was observed in rats at doses up to 100 mg/kg/day.

Pregnancy: Teratogenic Effects

Reproduction studies have been performed in rats and rabbits at chlorhexidine gluconate doses up to 300 mg/kg/day and 40 mg/kg/day, respectively, and have not revealed evidence of harm to the fetus. However, adequate and well-controlled studies in pregnant women have not been done. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

ADVERSE REACTIONS

The most common side effects associated with chlorhexidine gluconate oral rinses are; 1) an increase in staining of teeth and other oral surfaces; 2) an increase in calculus formation; and 3) an alteration in taste perception; see WARNINGS and PRECAUTIONS. Oral irritation and local allergy-type symptoms have been spontaneously reported as side effects associated with the use of chlorhexidine gluconate rinse.

The following oral mucosal side effects were reported during placebo-controlled adult clinical trials: aphthous ulcer, grossly obvious gingivitis, trauma, ulceration, erythema, desquamation, coated tongue, keratinization, geographic tongue, mucocele, and short frenum. Each occurred at a frequency of less than 1%.

Among post marketing reports, the most frequently reported oral mucosal symptoms associated with chlorhexidine gluconate oral rinse are stomatitis, gingivitis, glossitis, ulcer, dry mouth, hypesthesia, glossal edema, and paresthesia.

Minor irritation and superficial desquamation of the oral mucosa have been noted in patients using chlorhexidine gluconate oral rinse.

There have been cases of parotid gland swelling and inflammation of the salivary glands (sialadenitis) reported in patients using chlorhexidine gluconate oral rinse.

OVERDOSAGE

Ingestion of 1 or 2 ounces of chlorhexidine gluconate oral rinse by a small child (~10 kg body weight) might result in gastric distress, including nausea, or signs of alcohol intoxication. Medical attention should be sought if more than 4 ounces of chlorhexidine gluconate oral rinse is ingested by a small child or if signs of alcohol intoxication develop.

DOSAGE AND ADMINISTRATION

Chlorhexidine gluconate oral rinse therapy should be initiated directly following a dental prophylaxis. Patients using chlorhexidine gluconate oral rinse should be reevaluated and given a thorough prophylaxis at intervals no longer than six months.

Recommended use is twice daily oral rinsing for 30 seconds, morning and evening after tooth brushing. Usual dosage is 15 ml (marked in cap) of undiluted chlorhexidine gluconate oral rinse. Patients should be instructed to not rinse with water, or other mouthwashes, brush teeth, or eat immediately after using chlorhexidine gluconate oral rinse. Chlorhexidine gluconate oral rinse is not intended for ingestion and should be expectorated after rinsing.

HOW SUPPLIED

Chlorhexidine gluconate oral rinse is supplied as a blue liquid in

• 1-pint (473 ml) (NDC 68788-9546-4) amber plastic bottles with child-resistant dispensing closures

Store at 20°C to 25°C (68°F-77°F), excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP controlled Room Temperature]. Rx Only.

Revised: April 2022

Distributed by:

Xttrium Laboratories, Inc.

1200 E. Business Center Dr. Mount Prospect, IL 60056


Relabeled By: Preferred Pharmaceuticals Inc.

DESCRIPTION

NDC 0116-2001-16



0.12% chlorhexidine gluconate (CHG) is an oral rinse containing (1,1'-hexamethylene bis [5-(p-chlorophenyl) biguanide]di-D-gluconate) in a base containing water, 11 .6% alcohol, glycerin, PEG-40 sorbitan diisostearate, flavor, sodium saccharin, and FD&C Blue No.1. Chlorhexidine gluconate product is a near neutral solution (pH range 5-7). Chlorhexidine gluconate is a salt of chlorhexidine and gluconic acid. Its chemical structure is:



PRINCIPLE DISPLAY PANEL

NDC 68788-9546-4

CHLORHEXIDINE GLUCONATE 0.12% ORAL RINSE, USP

Direction for Use: Fill cap to the "fill line" (15ml). Swish in mouth undiluted for 30 seconds, then spit out. Use after breakfast and before bedtime. Or, use as prescribed.

Note: to minimize medicinal taste, do not rinse with water immediately after use.

Rx Only

KEEP OUT OF REACH OF CHILDREN

4 oz. (118 mL)

INGREDIENTS: 0.12% chlorhexidine gluconate in a base containing water, 11.6% alcohol, glycerin, PEG-40 sorbitan diisostearate, flavor, sodium saccharin and FD&C Blue No.1.

To open, press in flat pannels while turning cap. To reseal, turn cap past "clicks" until tightly locked.

WHAT TO EXPECT WHEN USING CHLORHEXIDINE GLUCONATE ORAL RINSE

Your dentist has prescribed chlorhexidine gluconate oral rinse to treat your gingivitis, to help reduce the redness and swelling of your gums, and also to help you control any gum bleeding. Use chlorhexidine gluconate oral rinse regularly, as directed by your dentist, in addition to daily brushing. Spit out after use, chlorhexidine gluconate oral rinse should not be swallowed.

If you develop allergic symptoms such as skin rash, itch, generalized swelling, breathing difficulties, light headedness, rapid heart rate, upset stomach or diarrhea, seek medical attention immediately. Chlorhexidine gluconate oral rinse should not be used by persons who have a sensitivity to it or its components.

Chlorhexidine gluconate oral rinse may cause some tooth discoloration, or increase in tartar (calculus) formation, particularly in areas where stain and tartar usually form. It is important to see your dentist for removal of any stain or tartar at least every six months or more frequently if your dentist advises.

Both stain and tartar can be removed by your dentist or hygienist. Chlorhexidine gluconate oral rinse may cause permanent discoloration of some front-tooth fillings.

To minimize discoloration, you should brush and floss daily, emphasizing areas which begin to discolor.


Chlorhexidine gluconate oral rinse may taste bitter to some patients and can affect how food and beverages taste. This will become less noticeable in most cases with continued use of chlorhexidine gluconate oral rinse.

To avoid taste interference, rinse with chlorhexidine gluconate oral rinse after meals. Do not rinse with water or other mouthwashes immediately after rinsing with chlorhexidine gluconate oral rinse.


If you have any questions or comments about Chlorhexidine gluconate oral rinse, contact your dentist, pharmacist, or Xttrium Laboratories, Inc. toll free at 1-800-587-3721.

Call your health care provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

STORE at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F) [See USP controlled Room Temperature].



DESCRIPTION: 0.12% chlorhoxidine gluconate (CH6) is an oral rinse contairing (1,1¹⁻hexamethylene bis [5-j-chlorophenylbiguanika] d-0-gluconate jin a base contairing water, 11.6% alchokal, glycain, PEG-40 orbita indicaterateri, Havy, colam escharian, and PASE Blue No.1. Chlorhoxidine gluconate product is a near neutral solution (pH range 5-7). Chlorhoxidine gluconate is a sait of chlorhoxidine and niconie acid. He. hemisel structure is



CLINICAL PHARMACOLOGY: Chlorbesidine glacosta cell rines provides antimicrobial activity during cell rines). The dischal aggingtheraction of chlorbesidine glacostate cell rines's antimicrobial antipate has a cell-antimicrobial matching and tangans has cell reserved involution of counts of certain assayed bacteria, both aerobis and araerobis ranging from 54-97% through aix morths use. Use of chlorbesidine glacostate cell rines in a aix month chlored insubjectorate in al rines in a aix month chlored insubjectorate in argo significant polantality apportunistic organisms or other adverse tranges in tacteria insocial accessione. Three OH H OH OH softer chlorhexidine gluconate oral rinse use iscortinued, the number of bacteria in plaque turned to basiline levels and resistance of a bacteria to chlorhexidine gluconate was to that at baseline.

Pharmacokinetics: Pharmacokinetic studies with chorhacidne gluconeta coral ince indicate approximately 30% of the active ingredient, chorhacidne gluconeta, is retained in the oral cavity following missing. This retained drug is slowly released in the oral fluids. Studies conducted on human subjects and animals demonstrate chorhacidne gluconeta is joordy desorbed from the guitorintestinal tract. The mean plasma level of chlorhexiting glucomean mached a peak of 0.256 morging in marine 30 matukes and the thyle levels of chlorhexiting glucomean version to the levels of chlorhexiting glucomean version and the the plasma of these subjects 12 hours, after the compound wess administered. Excerdion of chlorhexiting glucometia outgets the thorhexit the loces (-,00%). Less than 1% of the chlorhexiting glucometia ingested by these subjects was excerted

NDICATION: Chortexistine gluconate oral rines is indicated for use between dental visits as part of a production property of the significant of characteristical by relates and swelling of the glinpine. I including drug and lower up upon version, been teached among patients with earths necotisting ubsarding glinpints (NUIG, For patients having consisting glinpints of patients and period constraints glinpints and periodentifications who are Norman to be hypersensitive to chortholiciting glucomate or other formula strayed-area.

WARNINGS: The effect of chlorhexidine glucorate or of these on periodinis has not been elemented. An increase in appropried calculus was noted in increase in appropried actual was not an element users compared with control users. It is not known if holchhordine glucorate our in rus are routellis in an increase in subginghal calculus. Calculus deposits hould be removed by a dential prophysics at intervales not greater than aix months. Appropriate a intervale sericul aspect monored arising postmarketing use with dential products containing holchhordines. SC DITANUCICNINS.

PRECAUTIONS: General: 1. For natients having coexisting cincing

or planetin intering consisting gray-test and interchonthis, the presence or absence of dynamic high-maining glucorate out innue should not be seed as a major inclustor or underlying eriodonthis. Inchroadrine glucorate or all rinse an ausse taining of oral surfaces, such as to oft surfaces, testimation, and the document of the torque. Not all attents will experience a visually significant crease in tordhattining. In clinical testing, SGNs of cholomositine glucomate or all rinne users exhibited a messentile increase in facial anterior stein, compared to SGNs of control users after size morting, TSN of cholomositine glucomate and heavy ratin, compared to TNs of control users after size months. Stain will be more pronuous differ size months. Stain will be more pronuous differ size months. Stain will be more ground a deversity after cheshif or the appropriate or chick the stain of the appropriate or cher chall be a size of the static or the static of the prophytical techniques, Additional time may be additional the memory of professional appropriate techniques, Additional time may be additional the memory of profession and anterior facial restorations with rough autrascer and che seatures abin cannot be removed from these surfaces by a dental prophysics, patients with autrasceptable. Sain in these areas may be difficult to remove by dental prophysics and ne re a cossions may mesosible or leadors. 3. Some patients may experience an alteration in tastes perception while undraging transmittant with characteristic glucomate cert innes. Fare instances of permanent tasks alteration following the characteristic alteration glucomate cert instance and the second second second second perception of the second second second second action have been performed in task and rabbit at characteristic glucomate descent second second and 40 mg/slq/ sign respectively, and have not revealed configure of harm to fains. However, and 40 mg/slq/ sign respectively, and have not revealed configure of harm to fains. However, and and 40 mg/slq/ sign respectively, and have not revealed configure of harm to fains. However, and women have not have not have not alterna initial reproduction studies are not devejo predictive of pergramary only if clearly needed. Humine Medmenet is in on known schafter this

Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when chlorhexidine gluconate oral rinse is administered to nursing women. In perturbing and lactation studies with rats, no

In perturation and lactation studies with rats, no evidence of impaired parturation or of toxic effects to suckling pups was observed when chlorhexidine

distantiant discretion discretio discretion discretion discretion discretion discretion	Can be FA a "" ² μασποίοσα ² τη Disso 1000 ² τη Disso 1000 ² ² τη Disso 1000 ²	permitted to 19°C to 30°C (50°F to 86°F) [See USP controlled Room Temperature]. Manufactured by: Xthium Laboratories, Inc. 1200 E. Business Center Dr.	 To minimise devolvement, you whold thrush motions addily explosing means which begins to discuss. Borna dally, explosing means which begins to discuss the second sec	and nines to trady any pipelines. In this phonone the medicine and tradingly piper grants, and and no bala phonone and tradingly piper grants, and and no bala phonone and menangladay, and districted by yar- disocates and menangladay, and districted by yar- density, and data to solid healthing, single of affect metal-balance and the solid healthing and districted by the solid healthing and the solid healthing and the solid healthing and the solid healthing and distributions distribution and and the solid distributions distribution and and the solid healthing the solid healthing and the solid healthing and the solid healthing and the solid healthing and the solid for anticol, particular the reasons in the traj foldshild formation, particular the solid healthing and the solid healthing and the record of provide the solid healthing and the solid healthing and the record of provide the solid healthing and thealthing and thealthing and thealthing and thealth	platic rule (door ops) 0. 5-cross (15 ml pNC0115-2001-15 mbr platic belles with ch4 -axiant (across 4-cross (11 8 ml pNC0115-2001-16 mbr platic belles with ch40-control (across 1-cross) (12 ml platic) 10 Ke and (12 ml plat	Model affective activation was an end of the second activation of the s	reported diring placebo-controlled adult deviced triking adplaces alow cound down applicit, south the particle and one provide down applicit trappe, control trappe, leventication, groupplic trappe, methods and the provide down and a south and hereary point underling reports, the none forsyparity provide and muchidring reports, the none forsyparity and adult adult and adult adult adult adult adult and adult ad	weno over 100 Simos parter from the disk hold disknowling disknowling of the disk hold disk disknowling disknowling of the disk hold disk disknowling disknowling disk hold disk disknowling disk hold disk hold disk hold disk disk hold disk hold disk hold disk hold disk hold disk disk hold disk hold disk hold disk hold disk hold disk disk hold disk hold disk hold disk hold disk hold disk hold disk disk hold disk hold di
---	---	--	--	---	--	--	--	---

CHLORHEXIDINE GLUCONATE chlorhexidine gluconate rinse								
Product Info	rmation							
			Itom (`odo	NDC.697	00 OF 46		
Product Type		HUMAN PRESCRIPTIONItem CodeNDC:68788DRUG(Source)2001)			88-9546(NDC:0116-			
Route of Admin	istration	ORAL						
Active Ingredient/Active Moiety								
	Ingredient Name Basis of Stre						Strength	
CHLORHEXIDINE UNII:R4KO0DY52L)	CHLORHEXIDINE GLUCONATE (UNII: MOR84MUD8E) (CHLORHEXIDINE - CHLORHEXIDINE				_	1.2 mg in 1 mL		
Inactive Ingre	edients							
Ingredient Name						Strength		
GLYCERIN (UNII: P	DC6A3C0OX)							
PEG-40 SORBITAN DIISOSTEARATE (UNII: JL4CCU7I1G)								
ALCOHOL (UNII: 3K9958V90M)								
SACCHARIN SODIUM (UNII: SB8ZUX40TY)								
FD&C BLUE NO. 1	FD&C BLUE NO. 1 (UNII: H3R47K3TBD)							
WATER (UNII: 059QF0KO0R)								
Packaging								
# Item Code	Pa	ckage Description		Mark	eting Start Date		eting End Date	
1 NDC:68788- 9546-4	473 mL in 1 BC Product	OTTLE; Type 0: Not a Combin	nation	10/22/2	013			
Marketing	Informat	ion						
Marketing Category	Applicat	tion Number or Monog Citation	raph	Mar	keting Start Date	Mark	ceting End Date	

10/22/2013

ANDA

ANDA077789

Registrant - Preferred Pharmaceuticals, Inc. (791119022)

Establishment								
Name	Address	ID/FEI	Business Operations					
Preferred Pharmaceuticals, Inc.		791119022	RELABEL(68788-9546)					

Revised: 3/2024

Preferred Pharmaceuticals, Inc.